Regulatory Science: FDA Paths Forward With Real World Evidence Mitchell W. Krucoff, MD, FACC
|
|
|
- Lucy Sims
- 6 years ago
- Views:
Transcription
1 Regulatory Science: FDA Paths Forward With Real World Evidence 2017 Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director, MDEpiNet Coordinating Center Duke Clinical Research Institute [name of file], 1
2 Myths of The Parallel Universe Model: The Site-based Bottleneck in the USA Clinical Practice Clinical Research Higher quality = Higher cost: Larger cohorts Longer follow-up Faster enrollment More site-based burden
3 Addressing Therapeutic Innovation in the USA R&D Spending & New Rx Applications 10 Year Trends
4 : The Exodus of Industry & Device Research From the USA The reason, executives say, was that it would take too long to get its new cardiac stent approved by the FDA
5 The TREAT Initiative: Pragmatic Trial Designs for Public Health Issues Cardiac Safety & Bleeding Risk in Women 2010
6 Study of Access site For Enhancement of PCI for Women SAFE PCI for Women Sponsors*: NIH/NHLBI NCRI grant #: 1RC2HL FDA Office of Women s Health Acist Abbot Vascular Eli Lilly Medtronic Terumo *Sponsors: (<20 cents per dollar cost) [name of file], 6
7 Cath-PCI NCDR sites: SAFE-PCI for Women workflow Randomization Demographics Medical Hx Procedural data 65% site coordinator workload reduction Index Hosp MACE SAFE RCT pts: Autopopulate Part 11 Compliant DCRI DCRI Analytic Database 2.5 unique CRF pages for trial
8 September 2013 Lauer M et al, NEJM 2013 Hess C et al, Am Heart J 2013 Rao S et al JACC Cardiovascular Int 7(8)2014
9 SAFE STEMI for Seniors IDE 9 All Rights Reserved, Duke Medicine 2007
10 SAFE STEMI for Seniors: Linked NCDR-Claims Data Infrastructure: Device rich index hosp & long term follow up NCDR: Index Procedure Long Term Follow-up: CMS: Administrative Claims Data CRF Index data AMI from Clinical Registry Hospitalizatio n 1mo 1 yr 2 yrs 3 yrs 4 yrs 5 yrs Event ascertainment Death, MI, Stroke, Revasc Independent adjudication Months 10
11 MDRTF Report: August 24, 2015 CRNs: Leverage existing site-based work flow ( dual purpose not doubled work) Leverage EHR/registries implementing structured data No single repository sufficient for device evaluation Strategically linking complementary sources creates sufficiency Krucoff MW, Normand SL et al, JAMA 2015
12 NEST: The Vision Real World Evidence of Device Benefit/Risk, Safety More real world Less unique effort & cost More value across ecosystem: Regulatory decisions Best practice guidelines Payer decisions Patient information Learning model: Use/re-use structure solutions Linked architecture JAMA Published online July 11, 2016
13 Registries for embedding trials for regulatory decisions: Transforming real world data into real world evidence Data structure & quality
14 Disease Specific/Device Specific Data Elements: Defining a Minimum Core Data Set: The RAPID Roadmap CRFs: Pivotal trials Device & procedure Patient variables Device outcomes Clinical outcomes Registries: Best practices Device & procedure Patient variables Clinical outcomes EHRs: Clinical practice Report generators Device & procedure Patient variables Core Min Data Set: Clinical outcomes Common data elements Device non-specific: Pt descriptors Concomitant meds Device specific: Clin presentation Device model, mnfctr Procedural technique Operator training/exp Anatomic features Outcomes Health system workflow Common data model Device specific workflow
15 Disease Specific/Device Specific Data: Site-based Work Flow EHRs: Procedure reports Outcomes Claims: Coded supplies Coded services Core Minimum Data Set Structure: Enter once/use many Agnostic instantiation Agnostic implementation Transforming RW data into RW evidence Registries: Procedure reports Outcomes Inventory: Supplies Devices Tracking (pts) External data: Other registries Industry sources Etc
16 RAPID: 21 st Century (NEST) Trial Clinical Operations Model: Prospective RCT Clinical report work flow: Clinical descriptors Device identification Procedural information Outcomes of interest All Pts Electronic record systems: VQI NCDR EPIC Cerner VAMC SIR Part 11 compliant Clinical Trial Database: Clinical descriptors Device identification Procedural information Outcomes of interest Auto Study CRFs Study Pts Structured Core PAD Data Elements Study Site Coordinator Novel Ancillary Study Data (Core Laboratory, QOL)
17 Impact of consistent data structure over time: Statistical analytics Poolability & meta-analyses Bayesian analytics: exchangeability Longitudinal: generalizability of outcomes Newman AB, Contemporary Clinical Trials 46 (2016)
18 Progressive reduction in evidence burden: From one TPLC milestone to the next From breakthrough device to next generation devices Progressive leverage with upstream structured data: Frequentist: poolability, propensity Bayesian: exchangeability
19 Core Minimum Data Sets & NEST CRN Vision: With a continuous river of structured data you can float a lot of RCT boats If you don t have to re-build the river every single time Traditional Perspective 21 st Century Perspective
20 Regulatory Science: FDA Paths Forward With Real World Evidence 2017 Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Director, MDEpiNet Coordinating Center Duke Clinical Research Institute [name of file], 20
SAFE STEMI for Seniors: a PASSION proof of concept study
SAFE STEMI for Seniors: a PASSION proof of concept study Predictable And SuStainable Implementation Of National CardioVascular Registries Thinktank (PASSION CV Registries Thinktank) October 15, 2014 Proof
Registry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Pablo Morales, MD FDA Division of Cardiovascular Devices MDEpiNet Annual Meeting October 20, 2017 RAPID moving into full SPEED Pablo Morales,
Registry Assessment of Peripheral Interventional Devices (RAPID) Used to treat infrainguinal arterial occlusive disease
Registry Assessment of Peripheral Interventional Devices (RAPID) Used to treat infrainguinal arterial occlusive disease Goal: Standardize core data elements that could serve as a global case report form
Peripheral Arterial Disease
Peripheral Arterial Disease Registry Assessment of Peripheral Interventional Devices (RAPID) Launched June 5, 2015 Goal Standardize core data elements that could serve as a global case report form for
Piloting the National Cardiovascular Research Infrastructure: The SAFE-PCI for Women Trial
Piloting the National Cardiovascular Research Infrastructure: The SAFE-PCI for Women Trial Sunil V. Rao MD Associate Professor of Medicine Duke University Medical Center Duke Clinical Research Institute
CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action
CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action Danica Marinac Dabic, MD, PhD Director, Division of Epidemiology Summary FDA Strategic Priorities: 2016
Building the National Evaluation System for Medical Devices
Building the National Evaluation System for Medical Devices The Role of MDEpiNet PPP J. Matthew Brennan, MD, MPH Interventional Cardiology Duke Triangle Heart Associates Assistant Professor of Medicine
Registry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Used to treat infrainguinal arterial occlusive disease Goal: Standardize core data elements that could serve as a global case report form
Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice. Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology
Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology Summary RWE context Selected Examples of Early Successes and
Current State of Endpoint Adjudication in Device Trials Academic View
HARVARD MEDICAL SCHOOL Current State of Endpoint Adjudication in Device Trials Academic View CSRC/MDEpiNet Device Adjudication March 11, 2016 Donald E. Cutlip, MD Harvard Clinical Research Institute Smith
US Regulatory and Marketing Barriers for Medical Devices
US Regulatory and Marketing Barriers for Medical Devices September 8, 2015 Zvi Ladin, Ph.D. Principal Boston MedTech Advisors Boston Germany Israel 1 Regulatory Barriers Market Barriers (providers / payers)
CARDIOLOGY GRAND ROUNDS
CARDIOLOGY GRAND ROUNDS Presentation: Speaker: Date: Location: Approaching Efficiency in Randomized Clinical Trials in the US: The SAFE PCI for Women Experience Sunil V. Rao, MD, FACC, FSCAI Associate
Pragmatic Clinical Trials for Regulatory Decisions
Pragmatic Clinical Trials for Regulatory Decisions Jacqueline Corrigan-Curay, MD JD Office of Medical Policy Center for Drug Evaluation and Research FDA May 16, 2018 Pragmatic Clinical Trials Pragmatic
Coronary Stent Innovation: EPC Capture
Coronary Stent Innovation: EPC Capture Stephen Rowland Vice-President, Research & Development OrbusNeich Medical, Inc. HBD East 2017 Think Tank Meeting At National Institute of Global Health and Medicine
RAPID Phase 1 Deliverables Use Cases, Flow Diagrams
RAPID Phase 1 Deliverables Use Cases, Flow Diagrams James E. Tcheng, MD Duke Clinical Research Institute Durham, NC RAPID Think Tank 14 September 2016 1 Use Cases: Background & Rationale Why Use Cases?
Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST)
Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST) Bill Murray, President & CEO IDEAL Conference Presentation May 5, 2017 1 www.mdic.org Vision
Issues in Clinical Trial Designs for Devices
Issues in Clinical Trial Designs for Devices Soma Kalb, PhD Director, Investigational Device Exemption (IDE) Program Office of Device Evaluation Center for Devices and Radiological Health FDA Clinical
Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle
Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle Moderated by Karen Conway, GHX Panelists: Steven Luxenberg, MD, U.S. FDA CDRH Dennis Black, BD Robert Lynch, Franciscan
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular
Scott Gottlieb, MD Commissioner of Food and Drugs Food and Drug Administration New Hampshire Avenue Silver Spring, MD 20993
July 31, 2018 Scott Gottlieb, MD Commissioner of Food and Drugs Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Medical Device Safety Action Plan: Protecting Patients,
Clinical Trials and Medical Device Innovation in the US New Policies and Trends
Clinical Trials and Medical Device Innovation in the US New Policies and Trends Laura Mauri, MD, MSc Brigham and Women s Hospital Harvard Clinical Research Institute Medical Technology Innovation Scorecard
Introduction of Harmonization By Doing (HBD)
Introduction of Harmonization By Doing (HBD) 2003-2017 Mitchell W. Krucoff MD, FACC, FSCAI, FAHA Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit
Pharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
Resolute in the DES era: Indications & Limitations
Resolute in the DES era: Indications & Limitations Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac Catheterization Laboratory 11/6/2009 3rd CEEGI Advisory Board 1 3rd CEEGI
May 21, Moderator: Rachael Fleurence, PhD NESTcc Executive Director
The Changing Landscape of Health Care Decision-Making How can we Leverage the use of Real-World Evidence for Regulatory, Coverage, and Clinical Decision-Making? May 21, 2018 M EET YOUR PANELISTS! Moderator:
Current Issues in Device Development and Approval An Academic Perspec7ve
Current Issues in Device Development and Approval An Academic Perspec7ve Laura Mauri, MD, MSc Brigham and Women s Hospital Harvard Clinical Research Ins7tute Disclaimer The views and opinions expressed
Clinical Research and Adjudication
Clinical Research and Adjudication Rick Kuntz, MD, MSc Chief Scientific, Clinical and Regulatory Officer Medtronic, Inc. Medical Device Unanswered Questions Need for Surveillance Device performance: Efficacy
Evaluating therapies: Varying challenges in different eras Salim Yusuf
Evaluating therapies: Varying challenges in different eras Salim Yusuf Pre-1960 s: RCTs uncommon Large benefits undetected, unclear or not reliably demonstrated Large harms missed, e.g. 0 2 in newborns,
MDRTF / MDEpiNet August 20, 2015
P a g e 1 Recommendations for a National Medical Device Evaluation System Strategically Coordinated Registry Networks to Bridge Clinical Care and Research A Report from the Medical Device Registry Task
Accelerating Pre-Market Approval for Medical Devices
The National Academy of Sciences The Innovation Policy Forum Medical Devices Innovation: Opportunities, Threats, and Challenges Accelerating Pre-Market Approval for Medical Devices Michael J. Mack, MD
Cardiac Safety Research Consortium Annual Meeting. Future Areas of Focus & Opportunities 18 October 2016
Cardiac Safety Research Consortium Annual Meeting Future Areas of Focus & Opportunities 18 October 2016 CSRC MISSION To advance scientific knowledge on cardiac safety for new and existing medical products
Large, Simple Trials Policy Needs: Ethics, Trial Processes
Large, Simple Trials Policy Needs: Ethics, Trial Processes Conflicts I have and continue to conduct simple and complex trials funded by industry, NIH and foundations Industry relations can be found at
Keynote: Progress on the NEST Coordinating Center
1 Keynote: Progress on the NEST Coordinating Center Rachael Fleurence, Ph.D. NESTcc Executive Director July 20, 2017 The Ecosystem Challenge The health care ecosystem is united behind the need to improve
Framework for FDA s Real-World Evidence Program
Framework for FDA s Real-World Evidence Program Jacqueline Corrigan-Curay, J.D., M.D. Director, Office of Medical Policy Center for Drug Evaluation and Research Food and Drug Administration March 15, 2019
FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond
FDA s Center for Devices and Radiological Health: Strategic Priorities for 2017 and Beyond Jeff Shuren, MD, JD Center for Devices and Radiological Health U.S. Food and Drug Administration May 4, 2017 1
Transforming Validated Clinical Research into the new Cerner and EPIC App Stores (SMART FHIR)
Transforming Validated Clinical Research into the new Cerner and EPIC App Stores (SMART FHIR) Iltifat Husain MD Co-founder, IMPATHIQ Assistant Professor of Emergency Medicine Wake Forest School of Medicine
Pragmatic Clinical Trials
Pragmatic Clinical Trials Part II Christopher B. Granger, MD John P. Vavalle, MD Duke University Medical Center Pragmatic Clinical Trials Part I The importance of large clinical trials The need for evidence
Perspectives on Large Simple Trials
Perspectives on Large Simple Trials Michael S Lauer, MD, FACC, FAHA Director, Division of Cardiovascular Sciences National Heart, Lung, and Blood Institute Financial disclosures: None Clinical Trials Transformation
Re: Request for Permission to Release Data to the Cardiac Safety Research Consortium
Date: Re: Request for Permission to Release Data to the Cardiac Safety Research Consortium To: Dear Dr XXXX: We write to ask for your support in a collaborative effort sponsored by the Cardiac Safety Research
Interpreting Composite Endpoints in Cardiovascular in Clinical Trials
Interpreting Composite Endpoints in Cardiovascular in Clinical Trials Concepts and Controversies Paul W Armstrong MD ACC Rockies Banff Alberta March 13 2017 Disclosure Statement Paul W. Armstrong MD Research
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
The Right Data for the Right Questions:
The Right Data for the Right Questions: Evidentiary Needs as a Guide to Data Source Selection David Thompson, PhD Senior Vice President Louise Parmenter, PhD Global Head of Operations Real-World & Late
The Balance of Safety, Efficacy, and Reasonable Assurance in DES An FDA View
The Balance of Safety, Efficacy, and Reasonable Assurance in DES An FDA View Elizabeth Hillebrenner, MSE Interventional Cardiology Devices Branch Office of Device Evaluation Center for Devices and Radiological
WELCOME AND INTRODUCTIONS
S.M.A.R.T. Medical Device Informatics Think Tank Specific, Measurable, Achievable, Results-Oriented, Time Bound Collaboration WELCOME AND INTRODUCTIONS James Tcheng, M.D. Joseph P. Drozda, Jr., M.D. Terrie
Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Resnic FS, Majithia A, Marinac Dabic D, et al. Registry-based prospective,
Innovation in Adjudication A Case Study
Innovation in Adjudication A Case Study Gail Arias, RN Director, Endpoint Adjudication inventiv Health, Clinical Division Svetlana Gorodetsky VP Sales, IBM Watson Health, eclinical IBM Clinical Development
Clinical Study Design for Medical Devices
Clinical Study Design for Medical Devices Greg Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health U.S. Food and Drug Administration Kitasato-Harvard Symposium,
Medical Outcome Trials: Trends, Design Approaches and Operational Strategies for Success
Medical Outcome Trials: Trends, Design Approaches and Operational Strategies for Success Good Research Practice (GRP) Webinar Philip Galtry Patricia Steigerwald, MS, RN Copyright 2014 Quintiles Your Presenters
The BEST Platform. A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018
The BEST Platform A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018 Introduction The Bayesian early-phase seamless transformation (BEST) platform
Sentinel Journey from Safety Question to Regulatory Action. Rima Izem, PhD
Sentinel Journey from Safety Question to Regulatory Action Rima Izem, PhD rima.izem@fda.hhs.gov Food and Drug Administration Center for Drug Evaluation and Research Division of Biometrics 7 1 Disclaimer
Impact of Patient Engagement on Project Valuation
Impact of Patient Engagement on Project Valuation Bennett Levitan, MD-PhD Epidemiology, Janssen Research and Development CTTI Patient Groups & Clinical Trials Expert Meeting January 22, 2015 2 Disclosures
PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM
PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM INSIGHTS FROM YEAR 1 OF THE NIH COLLABORATORY Sean R. Tunis MD, MSc September 27, 2013 President and CEO Faculty/Presenter Disclosure Speaker Sean Tunis
Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Draft Guidance
Clinical Trial Methods Course 2017 Trials in Rare Diseases. Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017
Clinical Trial Methods Course 2017 Trials in Rare Diseases Erika Augustine, MD, MS University of Rochester Medical Center August 10, 2017 Overview Challenges in studying rare diseases Strategies for trial
Analytics. HealthView. Cardiovascular Data Intelligence.
HealthView Analytics Cardiovascular Data Intelligence www.lumedx.com info@lumedx.com Meaningful Data for Clinical and Operational Success Cardiovascular service lines are under tremendous pressure to perform
International Collaborative Studies in CVD - India Prem Pais MD Dean & Professor of Medicine St. John s Medical College
International Collaborative Studies in CVD - India Prem Pais MD Dean & Professor of Medicine St. John s Medical College Head, Clinical Trials Division St. John s Research Institute Bangalore St. John s
Leading Efforts to Tackle Roadblocks & Leverage Efficiencies. Jamie Roberts, MPH, MA, CCRP Director, Research Networks Duke CTSI
Leading Efforts to Tackle Roadblocks & Leverage Efficiencies Jamie Roberts, MPH, MA, CCRP Director, Research Networks Duke CTSI It takes a really long time Accelerate Translation The Vision for a Big,
Comparative Effectiveness and the United States Healthcare System: Success, Failure and Politics
Comparative Effectiveness and the United States Healthcare System: Success, Failure and Politics Michael C. Stoner, MD Division of Vascular Surgery What is CER? CER is the conduct of systematic research
Incorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting
Incorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting Washington Plaza Hotel Washington, DC January 15, 2016 Meeting
Data and Safety Monitoring Boards
Data and Safety Monitoring Boards Purposes, Roles and Challenges IACCT2017 Nov 29, 2017, Tel Aviv, Israel Arthur Weinstein, MD, FACP, FRCP, MACR Attending Rheumatologist Emeritus, MedStar Washington Hospital
Summary of Day 1. Christopher Granger
Summary of Day 1 Christopher Granger 508 million tweets Across the globe 2008 to 2010 Science Sept 30 2011 Selected Points Large simple trials are not so simple, and can also be called large streamlined
Non-Inferiority Trials: What are they and why are they so difficult?
Non-Inferiority Trials: What are they and why are they so difficult? David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research Saint-Luke Luke s s Mid America Heart Institute Professor of Medicine
Addressing the Ethical and Regulatory Issues in Pragmatic Clinical Trials
Keynote Address Addressing the Ethical and Regulatory Issues in Pragmatic Clinical Trials Jeremy Sugarman, MD, MPH, MA Harvey M. Meyerhoff Professor of Bioethics & Medicine Berman Institute of Bioethics
Management of Clinically Significant Device Attributes not Contained in the GUDID: Augmented Unique Device Identifier Data AUDI
Management of Clinically Significant Device Attributes not Contained in the GUDID: Augmented Unique Device Identifier Data AUDI Report of the MDEpiNet AUDI Workgroup MISSION: Provide the framework for
October 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
Re: Request for Permission to Release Data to the Cardiac Safety Research Consortium
Date: Re: Request for Permission to Release Data to the Cardiac Safety Research Consortium To: Dear Dr XXXX: We write to ask for your support in a collaborative effort sponsored by the Cardiac Safety Research
Cost of Current Industry- Based Device Evaluation
Cost of Current Industry- Based Device Evaluation Brad J. Martinsen, Ph.D. Director of Scientific Affairs, Clinical Cardiovascular Systems, Inc. (St. Paul, MN) MDEpiNet Registry Assessment of Peripheral
Moving UDI from Regulation to Value Within Hospitals and Beyond
Moving UDI from Regulation to Value Within Hospitals and Beyond Karen Conway Executive Director, Industry Relations, GHX Terrie Reed, MDEpiNet Coordinating Center Duke Clinical Research Institute Slide
Danica Marinac-Dabic, MD, PhD Division of Epidemiology
IMDRF Working Group: Integrating Device Registries and Innovative Tools for Medical Device Evaluation Danica Marinac-Dabic, MD, PhD Division of Epidemiology Scope Evaluate, compare & contrast current approaches
Navigating the Convergence of Payer and Regulator Evidence Requirements Opportunities and Challenges
Navigating the Convergence of Payer and Regulator Evidence Requirements Opportunities and Challenges Krista A. Payne Executive Director, Value Demonstration Principle Scientific Consultant Dr Janine Collins
Current Trends at FDA: Implications for Data Requirements
Introduction The environment surrounding medical device regulation in the United States has always been rigorous, but recent events including well-publicized quality issues associated with implantable
A Path from RWD to RWE Stopping Over at Statistical Inference
A Path from RWD to RWE Stopping Over at Statistical Inference ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2018 Scott Snyder, PhD Director, Statistics and Data Science Cook Research
Cytori Therapeutics. (NASDAQ: CYTX) Lazard Capital Markets 8th Annual Healthcare Conference November 16, 2011 Mark E. Saad, Chief Financial Officer
Cytori Therapeutics (NASDAQ: CYTX) Lazard Capital Markets 8th Annual Healthcare Conference November 16, 2011 Mark E. Saad, Chief Financial Officer 1 Safe Harbor Statement This presentation may contain
The Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
The Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Owen Faris, Ph.D. Director, Clinical Trials Program Office of Device Evaluation Center for Devices and Radiological
The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing
The Yale Open Data Access (YODA) Project: Lessons Learned in Data Sharing Grand Rounds: A Shared Forum of the NIH HCS Collaboratory and PCORnet June 30, 2017 Joseph S. Ross, MD, MHS Section of General
Leveraging Electronic Health Record (EHR) Data to Transform healthcare
Leveraging Electronic Health Record (EHR) Data to Transform healthcare Data-Driven Changes in Healthcare Lead to Improved Care and Lower Costs Nicole Hobbs, PhD Medical Informatics Director May 3, 2017
Rachael L. Fleurence, PhD NESTcc Executive Director. May 11, 2018
Rachael L. Fleurence, PhD NESTcc Executive Director May 11, 2018 THE ECOSYSTEM CHALLENGE The health care ecosystem is united behind the need to improve patients timely access to safe and effective devices
Optum One. The Intelligent Health Platform
Optum One The Intelligent Health Platform The Optum One intelligent health platform enables healthcare providers to manage patient populations. The platform combines the industry s most advanced integrated
Janus Clinical Trials Repository: Modernizing the Review Process through Innovation
Janus Clinical Trials Repository: Modernizing the Review Process through Innovation Lilliam Rosario, Ph.D. Director Office of Computational Science Food and Drug Administration Janus Clinical Trials Repository
UDI in the US. Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration. 19 October 2017
UDI in the US Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration 19 October 2017 UDI: Regulatory Update Terrie L. Reed, MS. Ind. Engineering Center for Devices and Radiological
CS19 KIRSTY LOUDON UNIVERSITY OF STIRLING
CS19 TREATMENT AS USUAL AS THE COMPARATOR IN RANDOMISED CONTROLLED TRIALS: A SCOPING REVIEW OF THE USE OF THE TERM OVER THE PAST FIVE YEARS IN SIX INTERNATIONAL GENERAL MEDICAL TRIAL JOURNALS. KIRSTY LOUDON
esource Advancement Roundtable
Clinical Research on FHIR Amy Nordo MMCi, BSN, RN, CPHQ, LNC Duke University Supported in part by Duke s CTSA grant (UL1TR001117) esource Advancement Roundtable August 2017 Duke University 3 Integrated
Enrollment Challenges in Cardiothoracic Surgical Clinical Trials
Enrollment Challenges in Cardiothoracic Surgical Clinical Trials Robert E. Michler, M.D. Surgeon-in-Chief Samuel I. Belkin Chair Professor and Chairman Department of Surgery Department of Cardiothoracic
QI, Research, Ethics Review Committees (aka, IRBs), and the SQUIRE 2.0 Guidelines. Greg Ogrinc, MD, MS December 6, 2015 IHI National Forum
QI, Research, Ethics Review Committees (aka, IRBs), and the SQUIRE 2.0 Guidelines Greg Ogrinc, MD, MS December 6, 2015 IHI National Forum How has SQUIRE been used? Write articles Abstracts and posters
V. Riambau, MD, PhD. Professor and Chief of Vascular Surgery Division CardioVascular Institute, Hospital Clinic, University of Barcelona
V. Riambau, MD, PhD Professor and Chief of Vascular Surgery Division CardioVascular Institute, Hospital Clinic, University of Barcelona vriambau@clinic.ub.es Consultant/Advisor Bolton Medical Cordis Bard
FDA UDI Demonstration. Joseph P. Drozda, Jr., M.D., F.A.C.C. Mercy Health
FDA UDI Demonstration Joseph P. Drozda, Jr., M.D., F.A.C.C. Mercy Health 34 ACUTE CARE HOSPITALS 4,396 LICENSED BEDS 36,917 CO-WORKERS 185 PHYSICIAN PRACTICE LOCATIONS 4,659 MEDICAL STAFF MEMBERS 1,235
Evolve or die: the urgent need to streamline randomized trials
Evolve or die: the urgent need to streamline randomized trials Rory Collins British Heart Foundation Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU),
CDISC Journal. Genzyme s GetSMART Program: Implementing Standards End-to-End
CDISC Journal Clinical Data Interchange Standards Consortium O ctober 2011 Genzyme s GetSMART Program: Implementing Standards End-to-End By Sue Dubman, Brooke Hinkson, Dana Soloff, David Fritsche and PK
Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide?
Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide? Vinod Nair MD FACC FSCAI Cardiovascular Ins6tute of the South, Houma Financial Disclosure:
Experience with Bayesian Clinical Trial Designs for Cardiac Medical Devices
Experience with Bayesian Clinical Trial Designs for Cardiac Medical Devices Andrew Mugglin Statistics Manager Cardiac Rhythm Management Clinical Research Medtronic, Inc. Acknowledgements with thanks to
Comparative Effectiveness Research. Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010
Comparative Effectiveness Research Informing Public and Private Payer Decision-Making Brian Sweet, Chief Pharmacy Officer June 24, 2010 How Evidence Begins No Evidence Beginning of Human Testing FDA Approval
Realities of UDI Capture: The Mercy/BUILD Experience
Realities of UDI Capture: The Mercy/BUILD Experience RAPID Workgroup, April, 2016 Joseph P. Drozda, Jr., M.D. Director of Outcomes Research The Mercy/BUILD UDI Strategy Integration of UDI into multiple
CTTI Overview One Decade of Impact. One Vision Ahead.
Feb. 6, 2018 CTTI Overview One Decade of Impact. One Vision Ahead. Pamela Tenaerts, MD, MBA Executive Director #CelebrateCTTI Discover how CTTI has influenced the clinical trials enterprise during the
Nuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards
Nuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards Ron Waksman, MD Professor of Medicine, Georgetown University Associate Chief of Cardiology, Washington Hospital Center
Scientific advice and its impact on marketing authorisation application reviews
Scientific advice and its impact on marketing authorisation application reviews SME info day: Tools to support innovative medicines development and early access Presented by Jan Regnström, MD, PhD Scientific
INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)
INVESTIGATIONAL DEVICE EXEMPTION APPLICATION IDE Title (if title being used) Name of Sponsor Investigator, MD X Professor, Department Icahn School of Medicine at Mount Sinai Date of Submission Form version
Regulatory Perspective on the Value of Bayesian Methods
American Course on Drug Development and Regulatory Sciences Substantial Evidence in 21st Century Regulatory Science Borrowing Strength from Accumulating Data April 21, 2016 Regulatory Perspective on the
Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation.
Webinar Tips Please mute your phone. Please do not put the call on hold. There will be time for questions after the presentation. Carolinas Collaborative Pilot RFA Webinar June 29, 2018 Partners Overview
Conflicts of Interest in Clinical Studies
Conflicts of Interest in Clinical Studies Steven Joffe, MD, MPH Assistant Professor of Pediatrics steven_joffe@dfci.harvard.edu ASGCT Clinical Trials Training Course May 18, 2010 1 Disclosure Information
Precision Vascular Robotics. Corindus Vascular Robotics (CVRS) January 2018
Precision Vascular Robotics Corindus Vascular Robotics (CVRS) January 2018 1 Forward Looking Statements This presentation contains forward-looking statements (as such term is defined in Section 27A of